Ticker brief
ALMS
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
3
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-29 → 2026-07-01 · now +0.12 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | -1.95 | 3 | +0.00 |
| @Omnitrader69 | C | -1.20 | 1 | +0.35 |
| @semodough | C | -0.75 | 1 | +0.25 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @Quantumup1 | +0.00 | UBS raises ORKA PT to 130 from 100 and reiterates Buy with bullish H2 data thesis. | · | tweet ↗ |
| 2026-07-01 | @semodough | +0.25 | ALMS expects Ph2b SLE data in 3Q26 and hopes for efficacy similar to AZN's Saphnelo. | · | tweet ↗ |
| 2026-06-30 | @Omnitrader69 | +0.35 | Recaps ALMS swing up to 28. | · | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | · | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.